Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 3/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12664018 | 0.83 | TP53 (0.50) | ALDH1A3DYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL798566 | 0.82 | PIK3CG (0.50) | DYRK1APIK3CDPIK3CAPIK3CG | |
| SCHEMBL3513815 | 0.82 | DYRK1A (0.64) | ALDH1A3DYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18613326 | 0.82 | ALDH1A3 (0.56) | ALDH1A3DYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3232733 | 0.82 | BRD4 (0.53) | ALDH1A3NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3263422 | 0.81 | DYRK1A (0.49) | ALDH1A3DYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13188559 | 0.79 | FYN (0.56) | PIK3CA | |
| SCHEMBL22275866 | 0.76 | KDM4E (0.50) | NPC1RAB9AALDH1A1KDM4EHPGD | |
| SCHEMBL936706 | 0.76 | PIK3CG (0.58) | ALDH1A3DYRK1ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31483039 | 0.75 | PIK3CA (0.61) | PIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| WO-2010007099-A1 | 2-AMINOIMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES AS PI3K INHIBITORS | CELLZOME LIMITED (GB) | 2010-01-21 | — | — | WO | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | ALDH1A3 3321/4885DYRK1A 1346/4885NPC1 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.